



ALLEN LEE COHN, M.D.

Business Address

Rocky Mountain Cancer Center-Midtown
1800 Williams Street
Denver, Colorado 80218
Telephone 303-388-4876
Fax 303-377-8375

Rocky Mountain Cancer Centers- Rose
4500 East 9th Street, Suite 600
Denver, CO 80220
Telephone 303-321-0302
Fax 303-321-9296

Date and Place of Birth

July 11, 1958
Chicago, Illinois

Licensure Status

State of Colorado

Board Certification

American Board of Internal Medicine, 1988
American Board of Internal Medicine, Medical Oncology,
1992

Education

September 1976 - December 1977
January 1978 - June 1980

Case Western Reserve University, Cleveland OH
University of Maryland Baltimore County,
B.A. Degree, Biologic Sciences

September 1980 - September 1981

University of Maryland Baltimore County,
M.S. Degree, Tumor Immunology

September 1981 - May 1985

University of Maryland, School of Medicine,
M.D. Degree

June 1985 - June 1986

Internship, University of Colorado Health Sciences Center,
Denver CO

July 1986 - June 1988

Residency - Internal Medicine, University of Colorado
Health Sciences Center, Denver CO

July 1988 - June 1991

Fellow, Hematology/Medical Oncology, University of
Colorado Health Sciences Center, Denver CO

Academic Appointments

July 1998 - November 1998

Associate Professor of Medicine, Division of Medical
Oncology, UCHSC

July 1997 - November 1998

Director, Clinical Cancer Center

July 1997 - November 1998

Associate Director for Clinical Affairs, University of
Colorado Cancer Center

October 1995 - June 1997

Acting Director, Clinical Cancer Center

July 1991 - June 1997

Assistant Professor of Medicine, Division of Medical

July 1990 - June 1991 Oncology, UCHSC
Instructor, Hematology/Medical Oncology, UCHSC

Positions Held

November 1998 – Present Medical oncologist, Rocky Mountain Cancer Centers
March 1998 - November 1998 Member, Quality, Safety, Risk and Credential Committee,
University Hospital Board of Directors
February 1998 - November 1998 Co-Chair, Ad Hoc Clinical Cancer Center Committee,
University Hospital
November 1996 - November 1998 Member, Board of Directors, Cancer Clinical Trials Task
Force
October 1996 - Present Member, Professional Advisory Board, Glaxo Wellcome
Oncology
April 1996 - Present Member, OpTx/AMC Clinical Advisory Board
May 1995 - Present Member, Task Force for Insurance Coverage of Clinical
Cancer Trials in Colorado
July 1994 - November 1998 Director, Quality Improvement, Department of Medicine 8
East and Cancer Center East Pavilion, UCHSC
March 1994 - April 1996 Principal Investigator, American Cancer Technologies
Research Program, University of Colorado
January 1994 - November 1998 University of Colorado Liaison Physician, American
College of Surgeons, Commission on Cancer
November 1993 - November 1998 Member, University Physicians Inc. Board of Directors
September 1991 - November 1998 Medical Director, East Pavilion Cancer Center, UCHSC
July 1991 - November 1998 Director, 8 East Oncology Inpatient Ward, University
Hospital, Denver CO
July 1991 - June 1995 Co-Director, Vascular Access Program, University of
Colorado Health Sciences Center, Denver CO

Community Service Positions Held

July 1996 - Present Member, Chartwell Rocky Mountain Region Clinical
Advisory Board
January 1996 - Present Member, Board of Directors, Visiting Nurse Association,
Denver, CO
June 1992 - Present Medical Director, Visiting Nurse Association Hospice at
Home
June 1992 - Present Member, Professional Advisory Board, Visiting Nurse
Association
February 1996 - Present Steamboat Springs Community Outreach Clinics,
once per month

Committees

August 1997 - November 1998 Vision 2020 Committee: Health Networks and Affiliates
August 1997 - November 1998 Vision 2020 Committee: Clinical Programs
July 1996 - November 1998 Chairman, Oncology Subcommittee, Pharmacy and
Therapeutics Committee
June 1996 - November 1998 Member, Pharmacy and Therapeutics Committee

1995 - November 1998	Member, Chemotherapy Task Force
June 1994 - November 1998	Co-Chair, Vascular Access Quality Committee, University of Colorado Health Sciences Center
1994 - November 1998	Chairman, Ambulatory/Inpatient Oncology Program
-	Subcommittee of the Lancer Committee
1994-1996	Co-Chair, Vascular Access Quality Committee
January 1993 - November 1998	Chairman, Cancer Committee, University of Colorado Health Sciences Center, Denver CO
1993-1994	University Faculty Representative, University Hospital and Rose Medical Center Joint Cancer Facility Planning
199") - 1994	Member, Medical Advisory Board for University Hospital and Rose Medical Center Joint Cancer Venture
1992 November 1998	Director, Quality Improvement (8East-EPAV) Committee
1992 - November 1998	Member, Cancer Center Protocol Review Committee
1991 - November 1998	Tumor Board

Awards and Honors

1976-1977	Vice-President's Scholarship Case Western Reserve University
1979 - Present	Phi Kappa Psi Honor Society, University of Maryland, Baltimore County
May 1980	Chancellor's Award for distinguished service to the University, University of Maryland, Baltimore County
1985 - Present	Alpha Omega Alpha National Medical Honor Society, University of Maryland Chapter
October 1993	President's Award, Medical Staff of University Hospital

Professional Societies

1992 - Present	American Society of Clinical Oncology
----------------	---------------------------------------

Clinical

Eight half-day clinics per week including clinics for Neuro-oncology, GI cancers, Head and Neck cancers, and general cancer cases.

Two months of inpatient attending per year on the Oncology ward.

Community outreach clinic monthly in Steamboat Springs CO.

Teaching

Med 6000, Pathophysiology Oncology

Clinical teaching of residents, fellows, medical students, and pharmacy students while attending on the inpatient oncology unit and outpatient cancer clinics.

Medical Oncology-Hematology Fellowship Lecture Series

Basic Research
1978-1982

University of Maryland, Baltimore County: Basic cell mediated immunity, tumor immunology, and regulation of surface histocompatibility antigens on tumor cells.

Clinical Research

1991 - present

University of Colorado Health Sciences Center: Phase II and Phase III clinical trials in the treatment of gastrointestinal malignancies, neuro-oncology, and head and neck cancer

Peer Reviewed Articles

1. Cohn AL: Regulation of the expression of major histocompatibility complex products on teratocarcinoma cells. Master's Thesis, University of Maryland, Baltimore County. September 1981.
2. Ostrand-Rosenberg S and Cohn AL: H-2 antigen expression on teratocarcinoma cells passaged in genetically resistant mice is regulated by lymphoid cells. *Proc. Natl. Acad. Sci. USA* 78:7106-7110, 1981.
3. Ostrand-Rosenberg S, Cohn AL and Cohan VL: Host regulation of major histocompatibility complex antigens on 402AX teratocarcinoma cells during tumor rejection. *Cold Spring Harbor Conferences on Cell Proliferation*, 10: 1983.
4. Ostrand-Rosenberg S, Cohn AL and Sandoz JW: Multiple splenic lymphoid cell populations regulate H-2 antigen expression on teratocarcinoma cells in vivo. *Journal of Immunology*, 130:2969-2973, 1983.
5. Gonzalez R, Sanchez A, Ferguson JA, Balmer C, Daniel C, Cohn A and Robinson WA: Melatonin therapy of advanced human malignant melanoma. *Melanoma Research*, 1:237-243, 1991.
6. Sanchez A, Robinson WA, Cohn A, Gonzalez R and Adlahka A: Low dose alpha interferon in the treatment of chronic myeloid leukemia. *Amer J Hem* 39:61-62, 1992.
7. Pearlman NW, Takach TJ, Robinson WA, Ferguson J, Cohn AL: A case-control study of late recurrence of malignant melanoma. *Am J of Surg* 164:458-461, 1992.
8. Haugep BR, Nawaz S, Cohn A, Shroyer K, Bunn PA, Liechty DR and Ridgway EC: Secondary malignancy of the thyroid gland: A case report and review of the literature. *Thyroid* 4:297-300, 1994.
9. Robinson JF, Robinson WA, Cohn A, Garg K, Armstrong JD: Perforation of the great vessels during central venous line placement. *Archives of Internal Medicine* 155:1225-1228, 1995.
10. Schrijvers D, Johnson J, Jiminez M, et al for the Head and Neck Interferon Cooperative Study Group: Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. *Journal of Clinical Oncology* 16(3):1054-1059, 1998.

Abstracts

1. Robinson WA, Gonzalez R, Cohn A, Sanchez A and Balmer C: A phase I-H study of melatonin in human malignant melanoma. IN P Hersey (ed.) *Biological Agents in the Treatment of Cancer*. Proc. of the International Conference, New Castle, Australia, pp. 511-526, 1990.
2. Leonard CD, Prasad K, Kumar I~, Cohn A: In vitro effect of taxol on squamous cell carcinoma of the head and neck. Presented at the American Association for Cancer Research, San Francisco CA, April 1994.
3. Leonard CE, Cohn A, Hintz R, Meyers CA: Alternating chemotherapy and accelerated hyperfractionated radiation therapy for advanced cancer of the head and neck. *Proceedings of American Society of Clinical Oncology*, Vol. 14, March 1995.

4. Clendeninn NJ, Collier MA, Johnston AL, Loh KY, Cohn AC, Kelly K, Glode LM, Stuart KE, Belani CP: Thymitaq' (AG337): A novel thymidylate synthase inhibitor with clinical activity in solid tumors. Proc AACR Vol 37, abstract #1176, page 171, 1996.
5. Loh K, Stuart K, Cohn A, et al: A phase II trial of Thymitaq (AG337) in patients with adenocarcinoma of the pancreas. Proceedings of the American Society of Clinical Oncology, Vol. 16, abstract #938, page 265a, 1997.
6. Rothenberg ML, Pazdur R, Rowinsky EK, Cohn AL, et al: A phase II multicenter trial of alternating cycles of irinotecan (CPT- 11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer (CRC). Proceedings of the American Society of Clinical Oncology, Vol. 16, abstract 9944, page 266a, 1997.
7. Belani CP, Lembersky B, Ramanathan R, Cohn A, et al: A phase II trial of Thymitaq (AG337) in patients with adenocarcinoma of the colon. Proceedings of the American Society of Clinical Oncology, Vol. 16, abstract #965, page 272a, 1997.
8. Belani CP, Aqarwala S, Johnson J, Cohn A, et al: A phase II trial of Thymitaq (AG337) in patients with squamous cell carcinoma of the head and neck. Proceedings of the American Society of Clinical Oncology, Vol. 16, abstract #1381, page 387a, 1997.
9. Petersen A, Johnston A, Clendennin NJ and THYMITAQ Phase II Investigators: Activity of THYMITAQ (Nolatrexed Dihydrochloride) in patients with squamous cell carcinoma of the head and neck. To be presented at the 2nd World Congress on Advances in Oncology, Athens Greece, October 16-18, 1997.

Book Chapters and Non Peer Reviewed Articles

1. Cohn AL: Colorectal carcinoma. In ME Wood and PA Bunn (eds) Hematology/Oncology Secrets. Hanley & Belfus, Philadelphia, pp. 280-282, 1994.
2. Cohn AL: Primary brain tumors. In ME Wood and PA Bunn (eds) Hematology/Oncology Secrets. Hanley & Belfus, Philadelphia, pp. 319-321, 1994.
3. Cohn A (Contributing Author), Seligman P (Associate Editor): Hematology and Oncology. In RW Schrier (ed) The Internal Medicine Casebook: Real Patients, Real Answers. Little, Brown and Company; Boston; pages 241-304, 1994.
4. Van Stieglmann G, Cohn AL, Nakano S: Cryodestruction. of hepatic tumors. Surgical Technology International III, pp 61-66, 1994.
5. Cohn AL: Chemotherapy for head and neck cancer. In BW Jafek and AK Stark (eds) ENT Secrets. Hanley and Belfus, Philadelphia, pp. 240-243, 1996.

Presentations and Posters

1. Ostrand-Rosenberg S, Cohn AL and Cohan VL: H-2 negative teratocarcinomas become H-2 positive when passaged in genetically resistant mice. Poster presented at 7th International Convocation on Immunology", State University of New York at Buffalo. July, 1980.
2. Cohn AL: Lymphoid cell regulation of antigen expression on 402AX teratocarcinoma cells. Paper presented at the Annual Meeting of the Immunology Council, Syria, Virginia. June, 1981.
3. Ostrand-Rosenberg S and Cohn AL: Regulation of MHC antigen expression on teratocarcinoma cells growing tolerant and resistant host mice. Poster presented at the Conference on Immunological Tolerance to Self and Non-self, New York Academy of Sciences. October 1981.
4. Cohn AL, Sandoz JW and Schwartzman M: H-2 antigen expression on the murine 402AX teratocarcinoma. Paper presented at the Annual Meeting of Immunology

Council, St. Mary's College, Maryland. April 1982.

5. Sanchez A, Robinson WA, Gonzalez R, Cohn A, Daniel C: Melatonin and malignant melanoma. Abstract presented at the International Conference on Biological Treatment of Melanoma and Other Cancers. September 1990.
6. Stiegmann G, Cohn A, Onik G, Pearlman N, Durham J, Hodges K, Thierno G, Kumpe D, McIntyre R: Laparoscopic guided ultrasonography staging and cryoblation of hepatic tumors. Presented at University of Colorado Cancer Center Third Annual Poster Session, Denver CO, November 1993.
7. Leonard C, Cohn A, Hintz R, Waitz D, Meyers A, Bunn P: Alternating chemotherapy and accelerated hyperfractionated radiation therapy for advanced cancer of the head and neck. Presented at University of Colorado Cancer Center Third Annual Poster Session, Denver CO, November 1993.
8. Leonard C, Prasad K, Kumar R, Cohn A: *In vitro* effect of taxol on squamous cell carcinoma of the head and neck. Presented at University of Colorado Cancer Center Third Annual Poster Session, Denver CO, November 1993.
9. Cohn A and Cook S: Chemotherapy for gliomas: Response and toxicities. Presented at "Malignant Gliomas: Challenges of Patient Management", Denver CO, January 1994.
10. Leonard CD, Prasad K, Kumar R, Cohn A: *In vitro* effect of taxol on squamous cell carcinoma of the head and neck. Presented at the American Association for Cancer Research, San Francisco CA, April 1994.
11. CPT-11 Presentation, Oncology Drug Advisory Committee, Food and Drug Administration, Washington DC, June 1996.
12. Loh K, Stuart K, Cohn A, et al: A phase II trial of Thymitaq (AG337) in patients with adenocarcinoma of the pancreas. Presented at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver CO, May 17-20, 1997.

13. Rothenberg ML, Pazdur R, Rowinsky EK, Cohn AL, et al: A phase 7 multicenter trial of alternating cycles of irinotecan (CPT- 11) and 5-FU/LV 'in patients wAh previously untreated metastatic colorectal cancer (CRQ. Presented at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver CO, May 17-210, 1997.
14. Belam CP, Lembersky B, Ramanathan R, Cohn A, et al: A phase II trial of Thymitaq (AG337) in patients with adenocarcinoma of the colon. Presented at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver CO, May 17-20, 1997.
15. Belani CP, Aqarwala S, Johnson J, Cohn A, et al: A phase H trial of Thymitaq (AG337) in patients with squamous cell carcinoma of the head and neck. Presented at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver CO, May 17-20, 1997.
16. Raich PC, Berris RF, Cohn A, DiBella N: Can HMOs be educated regarding cancer clinical trials? Presented at the American Association for Cancer Education annual meeting, October 1997.
17. Petersen A, Johnston A, Clendennin NJ and THYMITAQ Phase H Investigators: Activity of THYMITAQ (Nolatrexed Dihydrochloride) in patients with squamous cell carcinoma of the head and neck. Presented at the 2nd World Congress on Advances in Oncology, Athens Greece, October 16-18, 1997.
18. Cohn A: Chemotherapy for Gliomas. Presented at the Third Biennial: Team Up For Triumph, October 17-18, 1997, Denver CO.
19. Cohn A: Pancreatic cancer and weight loss. Presented at Recent Developments and Further Directions in the Research and Management of Anorexia and Cachexia, October 16-18, 1997, Cancun Mexico.
20. Cohn A: Advances in breast cancer diagnosis and treatment: An interactive panel discussion. Presented at Taking Care of Me, Routt Memorial Hospital, Steamboat Springs CO, July 23, 1998.